Log in

NASDAQ:CATBCatabasis Pharmaceuticals Stock Price, Forecast & News

$6.15
-0.11 (-1.76 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.97
Now: $6.15
$6.25
50-Day Range
$3.80
MA: $5.33
$6.37
52-Week Range
$2.74
Now: $6.15
$8.19
Volume173,092 shs
Average Volume153,155 shs
Market Capitalization$110.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Read More
Catabasis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$2.87 per share

Profitability

Net Income$-26,290,000.00

Miscellaneous

Employees24
Market Cap$110.09 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

How has Catabasis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Catabasis Pharmaceuticals' stock was trading at $4.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CATB shares have increased by 38.5% and is now trading at $6.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catabasis Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catabasis Pharmaceuticals.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Catabasis Pharmaceuticals.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) posted its earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.50) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.09. View Catabasis Pharmaceuticals' earnings history.

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Catabasis Pharmaceuticals's stock reverse split before market open on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CATB?

2 Wall Street analysts have issued twelve-month price targets for Catabasis Pharmaceuticals' stock. Their forecasts range from $15.00 to $60.00. On average, they anticipate Catabasis Pharmaceuticals' stock price to reach $45.00 in the next year. This suggests a possible upside of 631.7% from the stock's current price. View analysts' price targets for Catabasis Pharmaceuticals.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

News headlines about CATB stock have trended somewhat positive recently, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catabasis Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutCatabasis Pharmaceuticals.

Who are some of Catabasis Pharmaceuticals' key competitors?

What other stocks do shareholders of Catabasis Pharmaceuticals own?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the following people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 51)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 58)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 62)
  • Mr. Noah Clauser, VP of Fin. & Controller
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 54)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (17.03%), BlackRock Inc. (1.33%), Oppenheimer & Co. Inc. (0.60%), Geode Capital Management LLC (0.59%), RMB Capital Management LLC (0.40%) and WINTON GROUP Ltd (0.27%). View institutional ownership trends for Catabasis Pharmaceuticals.

Which major investors are selling Catabasis Pharmaceuticals stock?

CATB stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and WINTON GROUP Ltd. View insider buying and selling activity for Catabasis Pharmaceuticals.

Which major investors are buying Catabasis Pharmaceuticals stock?

CATB stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Orbimed Advisors LLC, Oppenheimer & Co. Inc., Geode Capital Management LLC, RMB Capital Management LLC, and BlackRock Inc.. View insider buying and selling activity for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $6.15.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $110.09 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-26,290,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. Catabasis Pharmaceuticals employs 24 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is www.catabasis.com.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.